Protagonist Therapeutics, Inc. has announced the nomination of PN-477, a potential best-in-class GLP-1, GIP, GCG receptor triple agonist peptide, as a development candidate for the treatment of obesity. The company is developing both an oral version, PN-477o, for once-daily dosing, and a subcutaneous version, PN-477sc, for once-weekly injection. The triple agonist is designed to optimize body weight loss, improve gastrointestinal tolerability, and enhance the fat to lean mass ratio, with the flexibility of oral and injectable routes of administration. IND-enabling studies are currently underway, with the initiation of Phase I clinical trials anticipated in the second quarter of 2026. Protagonist will provide further updates during a webcast and conference call scheduled for later today at 4:30 pm ET. Results from these studies will be presented in the future as they become available.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.